Senzime AB (publ) (STO:SEZI)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 709.04M |
| Revenue (ttm) | 104.02M |
| Net Income (ttm) | -137.42M |
| Shares Out | 157.22M |
| EPS (ttm) | -0.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52,042 |
| Average Volume | 186,253 |
| Open | 4.400 |
| Previous Close | 4.445 |
| Day's Range | 4.330 - 4.510 |
| 52-Week Range | 3.600 - 7.380 |
| Beta | 0.34 |
| RSI | 44.08 |
| Earnings Date | Feb 18, 2026 |
About Senzime AB
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue’s opposition to carrying an alternating electrical current. It also pr... [Read more]
Financial Performance
In 2025, Senzime AB's revenue was 104.02 million, an increase of 77.89% compared to the previous year's 58.48 million. Losses were -137.42 million, 15.7% more than in 2024.
Financial StatementsNews
Senzime AB (SNZZF) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Wins Propel ...
Senzime AB (SNZZF) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Wins Propel Future Outlook
Q4 2025 Senzime AB (publ) Earnings Call Transcript
Q4 2025 Senzime AB (publ) Earnings Call Transcript
Senzime AB (publ) (SNZZF) Q4 2025 Earnings Call Transcript
Senzime AB (publ) (SNZZF) Q4 2025 Earnings Call Transcript
Senzime Launches TetraCom Connectivity Platform Enabling Universal Transmission of Anesthesia Data
UPPSALA, SE / ACCESS Newswire / February 19, 2026 / Senzime AB (publ) (STO:SEZI)(OTCQX:SNZZF) today announced the launch of the TetraCom TM hospital connectivity platform. TetraCom is a first of its k...
Senzime AB (publ) GAAP EPS of -SEK0.27, revenue of SEK28.3M
Senzime AB (publ) 2025 Q4 - Results - Earnings Call Presentation
Senzime AB (publ) (SNZZF) Q4 2025 Earnings Call Prepared Remarks Transcript
Senzime AB (publ) (SNZZF) Q4 2025 Earnings Call Prepared Remarks Transcript
Senzime Secures Credit Line Facility of 50 MSEK
UPPSALA, SE / ACCESS Newswire / February 18, 2026 / Senzime AB (publ.) (STO:SEZI)(OTCQX:SNZZF) announces that the company has secured a credit line facility of 50 MSEK.
Senzime Q4 2025: Accelerated Growth and Continued Clear Path to Profitability
UPPSALA, SE / ACCESS Newswire / February 18, 2026 / Senzime AB's (publ.) (STO:SEZI)(OTCQX:SNZZF) year-end report for January - December 2025 is now available on the company's website www.senzime.com.
Invitation to Presentations of Senzime's Q4 and Year-End Report 2025
UPPSALA, SE / ACCESS Newswire / February 11, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime invites investors, analysts, and media to a webcast presentation of the fourth quarter and year-end report...
Senzime Secures Major Ivy League US Hospital System Contract
UPPSALA, SE / ACCESS Newswire / January 21, 2026 / Senzime AB (STO:SEZI)(OTCQX:SNZZF) today announced that it has secured another strategic contract in the US with a leading Ivy League university hosp...
Senzime's Next-Generation TetraGraph System Receives Regulatory Approval in Japan
UPPSALA, SE / ACCESS Newswire / December 17, 2025 / Senzime AB (publ.) (STO:SEZI)(OTCQX:SNZZF) today announced that its Next-generation TetraGraph® system has received regulatory clearance for sale in...
Senzime Unveils the Next Set of Innovations in Neuromuscular Monitoring With the Launch of EMGINE Sirius
UPPSALA, SE / ACCESS Newswire / December 10, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB (publ) today announced the launch of the latest series of innovative features for its next-generation T...
Senzime Secures Major TetraGraph Order from Leading UK NHS Hospital System
UPPSALA, SE / ACCESS Newswire / December 9, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB (publ.) today announced that one of the leading NHS hospital trusts in the United Kingdom (UK) has order...
Senzime to Present at Redeye and BioStock Investor Conferences
UPPSALA, SE / ACCESS Newswire / November 11, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF), a leader in solutions for personalized anesthesia, today announced that Philip Siberg, CEO of Senzime, will be pres...
Nomination Committee for Senzime Annual General Meeting 2026
UPPSALA, SWEDEN / ACCESS Newswire / November 3, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - A Nomination Committee consisting of shareholder representatives has been established for Senzime AB (publ.) in...
Senzime AB (publ) (SNZZF) Q3 2025 Earnings Call Prepared Remarks Transcript
Senzime AB (publ) (OTCQX:SNZZF) Q3 2025 Earnings Call October 29, 2025 6:00 AM EDT Company Participants Philip Siberg - Chief Executive Officer Presentation Philip Siberg Chief Executive Officer Okay....
Senzime Q3 2025: Strong Growth and Clear Steps Towards Profitability
UPPSALA, SE / ACCESS Newswire / October 29, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB's (publ) interim report for January - September 2025 is now available on the company's website www.senzi...
Invitation to Presentations of Senzime's Third Quarter 2025 Report
UPPSALA, SE / ACCESS Newswire / October 23, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime invites investors, analysts, and media to a webcast presentation of the third quarter report for 2025 on Oc...
Senzime Launches EMGINE, The Next-Generation Software Suite Advancing Neuromuscular Monitoring
UPPSALA, SE / ACCESS Newswire / October 8, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB (publ) today announced the launch of EMGINETM, a proprietary software suite for its next-generation Tetra...
Senzime Welcomes New European Pediatric Guidelines Recommending EMG-Based Neuromuscular Monitoring
UPPSALA, SE / ACCESS Newswire / October 3, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime AB (publ) welcomes today's presentation at the ESPA congress in Berlin of the first-ever pediatric guidelines ...
Senzime Awarded Contract to Supply the U.S. Department of Defense and Walter Reed National Military Medical Center
UPPSALA, SE / ACCESS Newswire / September 17, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime AB (publ) today announces that the U.S. Department of Defense has awarded a contract to supply the TetraGra...
Senzime to Present at Pareto Securities' 16th Annual Healthcare Conference
UPPSALA, SE / ACCESS Newswire / September 12, 2025 / Senzime AB (Nasdaq Stockholm:SEZI)(OTCQX:SNZZF), a leader in precision-based monitoring during anesthesia, today announced that the company will pa...
Senzime Launches Integration with Mindray Patient Monitors
UPPSALA, SE / ACCESS Newswire / September 12, 2025 / Senzime AB (publ) today announced the launch of new connectivity solutions to external data platforms, monitors, and electronic health records. The...
Senzime Welcomes New Japanese Guidelines on Neuromuscular Monitoring
UPPSALA, SE / ACCESS Newswire / September 9, 2025 / Senzime AB (publ) (STO:SEZI)(OTCQX:SNZZF) - today announced that the Japanese Society of Anesthesiology (JSA) has published updated clinical guideli...